Immunotherapy resistance remains a critical limitation in oncology, particularly in microsatellite stable (MSS) tumors. ENB-003, a first-in-class selective endothelin B receptor (ETBR) inhibitor, targets immune exclusion by restoring T-cell trafficking into tumors.
Colon cancer remains one of the most preventable yet under- detected cancers in the United States, particularly among underserved communities. HITLAB is conducting this marketing and impact study on behalf of Grapevine Health to assess the effectiveness of a six-part colon cancer screening health literacy
video series.
HITLAB researchers conducted a thorough evaluation of the VitalFriend’s platform, in the form of a heuristic evaluation. The evaluation focused on platform usability; BUDDI was reviewed only as a representative integrated device. A heuristic evaluation identified strengths in usability and areas for improvement in navigation clarity, alert prioritization, and onboarding workflows.
Healthcare delivery often misses early deterioration due to episodic care, while integrated remote patient monitoring enables proactive management—though gaps in automation, integration, and data usability still limit its full impact. This study presents HITLAB’s heuristic evaluation of PreventCare, a digital health platform designed to automate remote vital sign capture and integrate patient-generated data into clinical workflows. The evaluation identified strong alignment with preventive care goals, intuitive design patterns, and meaningful clinical insights. However, usability gaps were identified in personalization, clarity of data interpretation, onboarding, and workflow transparency. Addressing these gaps can enhance user trust, clinical efficiency, and scalability of remote monitoring.
Independent validation initiative will deliver peer-reviewed, real-world evidence behind Evida Health’s AI-powered compliance platform — clearing the path from hospital pilots to full-scale adoptio





